Compare Enveric Biosciences Inc (ENVB) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Vanguard Total World Stock Index Fund ETF trades at $156.08. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | VT | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.40 | $159.35 |
52-Week Low | $1.28 | $128.41 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
The Vanguard Total World Stock ETF (VT) trades at $156.24, down 0.34% on the day. Technical indicators show a bullish trend from moving averages, with neutral oscillators suggesting consolidation near key support at $155. The fund provides global equity diversification with over 10,000 holdings across developed and emerging markets, maintaining a low expense ratio of 0.06%.
VT offers comprehensive global exposure but faces competition from lower-cost alternatives. The fund's broad diversification reduces single-country risk, though its performance remains tied to global economic conditions. A dividend of $0.56 per share is scheduled for payment on June 23, 2026, providing income alongside growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
